The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization and relative value of breast cancer adjuvant chemotherapy regimens in the community.
D. A. Patt
Employment or Leadership Position - US Oncology
J. L. Espirito
No relevant relationships to disclose
B. Turnwald
No relevant relationships to disclose
J. R. Hoverman
Employment or Leadership Position - US Oncology
M. A. Neubauer
Employment or Leadership Position - US Oncology
T. H. Cartwright
Consultant or Advisory Role - Amgen; Genentech; Lilly; Sanofi
Honoraria - Amgen; Lilly; Roche; Sanofi
B. D. Brooks
Consultant or Advisory Role - Amgen
Honoraria - Eisai
L. T. Busby
No relevant relationships to disclose
M. A. Sitarik
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - Eisai; Pfizer (U)
Honoraria - Eisai; Pfizer
M. A. Kolodziej
Employment or Leadership Position - US Oncology
A. L. Ginsburg
No relevant relationships to disclose
S. Sheth
No relevant relationships to disclose
J. S. Garey
No relevant relationships to disclose
M. Clayton
No relevant relationships to disclose
G. C. Nelson
No relevant relationships to disclose
R. W. Anderson
No relevant relationships to disclose
R. A. Beveridge
Employment or Leadership Position - US Oncology
Honoraria - US Oncology
Research Funding - US Oncology